Natera (NTRA) president sells 2,213 shares to cover RSU tax obligations
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, reported small insider sales of common stock tied to RSU vesting. On January 27, 2026, he sold 1,013 shares at $240.5313, and on January 28, 2026 he sold 1,200 shares at $237.6624.
The filing states both sales were made to satisfy tax withholding and remittance obligations from restricted stock unit vesting, under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, he directly owns 142,486 shares of Natera common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,213 shares ($528,853)
Net Sell
2 txns
Insider
Moshkevich Solomon
Role
PRESIDENT, CLINICALDIAGNOSTICS
Sold
2,213 shs ($529K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,200 | $237.6624 | $285K |
| Sale | Common Stock | 1,013 | $240.5313 | $244K |
Holdings After Transaction:
Common Stock — 142,486 shares (Direct)
Footnotes (1)
- The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.
FAQ
What insider transaction did Natera (NTRA) report for Solomon Moshkevich?
Natera reported that executive Solomon Moshkevich sold 1,013 shares on January 27, 2026 and 1,200 shares on January 28, 2026. Both transactions involved Natera common stock and were disclosed on a Form 4 insider trading report.
What is Solomon Moshkevich’s role at Natera mentioned in the Form 4?
The Form 4 identifies Solomon Moshkevich as an officer of Natera with the title “President, Clinical Diagnostics.” This indicates he is a senior executive responsible for Natera’s clinical diagnostics segment and subject to Section 16 insider reporting rules.
What does the Form 4 say about Rule 10b5-1(c) in relation to these Natera trades?
The filing explains the sales were made under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. This language indicates the trades followed a pre-established plan tied to RSU vesting and tax obligations.